RecruitingPHASE1, PHASE2NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vironexis Biotherapeutics Inc.
- Principal Investigator
- Vironexis Clinical TrialsVironexis Biotherapeutics Inc.
- Intervention
- Dose Level 1, VNX-101(genetic)
- Enrollment
- 32 enrolled
- Eligibility
- 13-90 years · All sexes
- Timeline
- 2025 – 2031
Study locations (9)
- City of Hope, Duarte, California, United States
- Valkyrie Clinical Trials, Los Angeles, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- New York Medical College, Valhalla, New York, United States
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill, North Carolina, United States
- The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- TriStar BMT, Nashville, Tennessee, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06533579 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University